At the 2025 European Society of Medical Oncology (ESMO) Congress, held from October 17–21, results from the Phase III RC48-C016 study were presented, evaluating the combination of RemeGen Biosciences’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback